inroads in collaborations with the industry and some of the work getting commercialised .
How do you look at the biotech R & D scenario in India ? Are we innovating enough ?
Over the last few decades , the Indian pharma industry has strengthened its expertise in manufacturing and supplying quality generic drugs to address the growing need for affordable health care around the world . Both the government and industries in India have an aspirational growth outlook and we see the industry in India focusing on complex Biologics and other emerging novel modalities . According to and E & Y report , India is the third-largest global manufacturer of drugs , but it ranks 14th in terms of value .
The need of the hour is to further step up the R & D ecosystem in India , which establishes the Indian pharma industry not only in the generics space but also in biologics . The Indian Ministry of Science and Technology has created research ecosystems through its biotech parks and incubators . There is a huge potential to establish the country as the global innovation hub of the future . This would need more investments in R & D , collaborations between Industry and academia and funding from the government and private parties .
How can training and skill development enable professionals in our domestic life sciences industries ?
Collaborative steps between academia and industry can facilitate a better ecosystem in the country . The Indian Ministry of
“
The need of the hour is to further step up the R & D ecosystem in India , which establishes the Indian pharma industry not only in the generics space but also in biologics .
Science and Technology has created research ecosystems through its biotech parks and incubators . These kinds of facilities will enable opportunities to our younger generations to thrive in STEM education and learning cutting edge technologies that are most relevant . We need to invest in research programs to develop vaccines and therapeutics and provide training to leverage biotechnology . We need to spur innovation and entrepreneurship amongst the younger minds and help them develop products to solve real life problems . We need a strong research system that encourages independent thinking , bold ideas and a new generation of scientists and world leaders .
Your outlook for the innovative biotech and bioprocessing technologies in the next five years ?
We expect a sea change in the biotech landscape in India and globally . Over the past few years , we have seen significant investments and advancements in both traditional and novel modalities . We see a greater number of biosimilars getting approved for use globally . There are many companies working on novel modalities like , Cell & Gene Therapy , ADC ( Antibody-drug Conjugates ), HP-API ( highpotency API ), viral vector , and mRNA ( Messenger Ribonucleic acid ). For COVID vaccines , under development protein sub unit , viral vector , and nucleic acid based vaccines are the top modalities being explored by companies and molecules are at different stages of development .
We also anticipate the manufacturing landscape transforming in the biotech space over the next 5 years . Efforts towards making biosimilars or Mabs more affordable in order to be competitive globally and widen the market opportunity and is in line with the vision Government has for healthcare and pharma Industry . The focus has been on improving the yield of the products , driving down cost of manufacturing , improving efficiency of the products using continuous processing , manufacturing units moving from multi use to single use technologies and many more .
Your future outlook for Merck Life Sciences India ?
At Merck , our goal is to invest in using path breaking technologies to simplify treatment and make it accessible to all those in need , in collaboration with drug manufacturers across the world and scale up to make treatments and therapies available to all .
Our recent acquisitions has enabled us to become of the leading CMO players in mRNA vaccines and Gene therapy , offering an integrated CDMO across the value chain pre-clinical to commercial . In addition , we have also launched new product platforms for gene therapy and have specialized teams , enabling our customers to bring new curative treatments to market .
24
BioVoiceNews | October 2022